New research from the Mayo Clinic identified three factors that significantly affected survival for pancreatic cancer patients. The findings were published today (2nd April) in the medical journal, Annals of Surgery.
In response to the results Anna Jewell, Director of Research at Pancreatic Cancer UK, said:
“These findings are another promising indication of the impact chemotherapy could have for pancreatic cancer patients whose tumour is advanced, but yet to spread to other parts of the body. More evidence is still needed to help us understand how best to use chemotherapy and radiotherapy to make more people in this particular group of patients eligible for surgery but the emerging evidence is showing a real opportunity to improve overall survival, which has been appallingly low for 40 years.
“Currently only one in ten pancreatic cancer patients has surgery – the only potential cure for this devastating disease – because many are simply not treated fast enough. A clinical pathway is not in place across the UK to match the ferocity of pancreatic cancer. We need to see significant changes to how treatment is delivered if patients are to benefit from new developments in our understanding of how best to take on pancreatic cancer.”